Your browser is no longer supported. Please, upgrade your browser.
Index- P/E- EPS (ttm)- Insider Own22.52% Shs Outstand17.35M Perf Week1.45%
Market Cap246.12M Forward P/E- EPS next Y-3.84 Insider Trans-0.16% Shs Float14.95M Perf Month-38.53%
Income- PEG- EPS next Q-0.84 Inst Own73.00% Short Float3.46% Perf Quarter-15.57%
Sales- P/S- EPS this Y-107.00% Inst Trans-0.71% Short Ratio5.59 Perf Half Y-30.15%
Book/sh5.46 P/B2.57 EPS next Y-0.50% ROA- Target Price- Perf Year-
Cash/sh5.48 P/C2.56 EPS next 5Y- ROE- 52W Range12.90 - 62.71 Perf YTD-36.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.61% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low8.84% ATR1.49
Employees16 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)31.45 Volatility3.32% 7.30%
OptionableNo Debt/Eq0.00 EPS Q/Q-23.70% Profit Margin- Rel Volume0.90 Prev Close14.05
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume92.73K Price14.04
Recom1.30 SMA20-21.30% SMA50-33.51% SMA200-40.09% Volume83,570 Change-0.07%
Aug-17-20Upgrade Citigroup Neutral → Buy $34 → $30
Jun-30-20Downgrade Citigroup Buy → Neutral $30 → $34
Apr-06-20Initiated SVB Leerink Outperform $25
Apr-06-20Initiated Morgan Stanley Overweight $35
Apr-06-20Initiated Cowen Outperform $25
Jan-20-21 07:00AM  
Jan-06-21 05:21PM  
Dec-10-20 01:01AM  
Dec-07-20 07:00AM  
Nov-30-20 10:36PM  
Nov-17-20 07:00AM  
Nov-05-20 07:00AM  
Oct-31-20 08:00AM  
Oct-29-20 07:00AM  
Oct-16-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 07:00AM  
Aug-14-20 08:26AM  
Aug-13-20 04:01PM  
Aug-07-20 07:00AM  
Jul-30-20 07:00AM  
Jun-29-20 04:01PM  
Jun-25-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 01:57PM  
Jun-13-20 08:44AM  
Jun-12-20 07:46AM  
May-21-20 07:00AM  
May-07-20 07:00AM  
May-06-20 07:00AM  
May-04-20 07:00AM  
Apr-23-20 07:00AM  
Mar-11-20 09:57PM  
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ballal Rahul D.Chief Executive OfficerDec 17Option Exercise3.154,99915,7474,999Dec 21 04:47 PM
Ballal Rahul D.Chief Executive OfficerDec 17Sale25.004,999124,9750Dec 21 04:47 PM
GRAY MICHAELCFO & COODec 11Option Exercise4.921,2506,1501,250Dec 15 04:26 PM
GRAY MICHAELCFO & COODec 11Sale25.001,25031,2500Dec 15 04:26 PM